141 related articles for article (PubMed ID: 38812500)
1. Antibody responses in blood and saliva post COVID-19 bivalent booster do not reveal an Omicron BA.4/BA.5- specific response.
Baker R; Lawlor R; Smith M; Price J; Eaton A; Lover A; Alfandari D; Reinhart P; Arcaro KF; Osborne BA
Front Immunol; 2024; 15():1401209. PubMed ID: 38812500
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
[TBL] [Abstract][Full Text] [Related]
3. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM; Tan NH; Rietdijk WJR; Geers D; Sablerolles RSG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Rugebregt S; Goorhuis A; Postma DF; Visser LG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; Haagmans BL; van Baarle D; Koopmans MPG; ; van der Kuy PHM; GeurtsvanKessel CH; de Vries RD
Nat Commun; 2024 May; 15(1):4224. PubMed ID: 38762522
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
[TBL] [Abstract][Full Text] [Related]
5. Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals.
Klingler J; Lambert GS; Itri V; Liu S; Bandres JC; Enyindah-Asonye G; Liu X; Simon V; Gleason CR; Kleiner G; Chiu HP; Hung CT; Kowdle S; Amanat F; Lee B; Zolla-Pazner S; Upadhyay C; Hioe CE
Front Immunol; 2021; 12():759688. PubMed ID: 34987505
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
[TBL] [Abstract][Full Text] [Related]
8. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines.
Bowen JE; Addetia A; Dang HV; Stewart C; Brown JT; Sharkey WK; Sprouse KR; Walls AC; Mazzitelli IG; Logue JK; Franko NM; Czudnochowski N; Powell AE; Dellota E; Ahmed K; Ansari AS; Cameroni E; Gori A; Bandera A; Posavad CM; Dan JM; Zhang Z; Weiskopf D; Sette A; Crotty S; Iqbal NT; Corti D; Geffner J; Snell G; Grifantini R; Chu HY; Veesler D
Science; 2022 Aug; 377(6608):890-894. PubMed ID: 35857529
[TBL] [Abstract][Full Text] [Related]
9. Functional antibody responses targeting the Spike protein of SARS-CoV-2 Omicron XBB.1.5 in elderly nursing home residents following Wuhan-Hu-1-based mRNA booster vaccination.
Sánchez-Simarro Á; Fernández-Soto D; Grau B; Albert E; Giménez E; Avilés-Alía AI; Gozalbo-Rovira R; Rusu L; Olea B; Geller R; Reyburn HT; Navarro D
Sci Rep; 2024 May; 14(1):11896. PubMed ID: 38789475
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
[TBL] [Abstract][Full Text] [Related]
11. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
[TBL] [Abstract][Full Text] [Related]
12. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
13. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
14. Omicron breakthrough infections after triple-dose inactivated COVID-19 vaccination: A comprehensive analysis of antibody and T-cell responses.
Xiang T; Quan X; Jia H; Wang H; Liang B; Li S; Wang X; Li H; Feng X; Fan L; Xu L; Wang T; Xiong S; Yang D; Liu J; Zheng X
Immunology; 2024 Jun; 172(2):313-327. PubMed ID: 38462236
[TBL] [Abstract][Full Text] [Related]
15. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
[TBL] [Abstract][Full Text] [Related]
16. A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.
Usdan L; Patel S; Rodriguez H; Xu X; Lee DY; Finn D; Wyper H; Lowry FS; Mensa FJ; Lu C; Cooper D; Koury K; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
Clin Infect Dis; 2024 May; 78(5):1194-1203. PubMed ID: 38016021
[TBL] [Abstract][Full Text] [Related]
17. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
[TBL] [Abstract][Full Text] [Related]
18. Omicron neutralization character in patients with breast cancer and liver cancer after the nationwide omicron outbreak.
Zhang S; Tang L; Bao C; Wang S; Li B; Huang L; Song H; Fu J; Xu Z; Meng F; Cao L; Gao Y; Yuan Y; Chen Y; Yuan J; Zhou C; Li F; Qin L; Guo Y; Zhang C; Song J; Fan X; Jiang Z; Wang FS; Xu R
Cancer Med; 2024 Jun; 13(11):e7304. PubMed ID: 38826094
[TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
[TBL] [Abstract][Full Text] [Related]
20. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
